Characterization of the In Vitro and In Vivo Metabolism and Disposition and Cytochrome P450 Inhibition/Induction Profile of Saxagliptin in Human

Discovery and Preclinical Profile of Saxagliptin (BMS-477118):  A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

David J. Augeri, Jeffrey A. Robl, David A. Betebenner et al. · Journal of Medicinal Chemistry · 2005 · 621 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

The Glucagon-Like Peptides

Timothy J. Kieffer · Endocrine Reviews · 1999 · 219 citations · Full text

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

Lisa J. Christopher, Donghui Cui, Chi‐Yuan Wu et al. · Drug Metabolism and Disposition · 2008 · 197 citations

Medicine, Pharmacokinetics, Pharmacology +13

Mice With a Deletion in the Gene for CCAAT/Enhancer-Binding Protein β Are Protected Against Diet-Induced Obesity

Carrie A. Millward, Jason D. Heaney, David S. Sinasac et al. · Diabetes · 2006 · 105 citations · Full text

Life Sciences, Molecular Genetics, Gene Expression +13

Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections

Aberra Fura, Ashish K. Khanna, Viral Vyas et al. · Drug Metabolism and Disposition · 2009 · 99 citations

Pharmacy, Pharmacokinetics, Pharmacology +14